Technetium-99m labeled somatostatin-derived peptides for imaging
AssigneeDiatech, Inc.
InventorsRichard T. Dean, John Lister-James, Scott Buttram
Life of this patent
Estimating the term…
Abstract
The invention relates to radiolabeled imaging of a mammalian body. The invention in particular provides for reagents labeled with technetium-99m for such imaging. The invention specifically provides somatostatin, somatostatin derivatives, somatostatin analogues or peptides that bind to the somatostatin receptor and contain at least 2 cysteine residues that form a disulfide or wherein the disulfide is reduced to the sulfhydryl form that are directly labeled with technetium-99m and that can be targeted to specific sites within a mammalian body for imaging.
Claims6
A reagent for preparing a technetium-99m labeled peptide for imaging target sites within a mammalian body, the reagent comprising between 5 and 100 amino acid residues and at least 2 cysteine residues capable of forming a disulfide bond, wherein the reagent is directly labeled with technetium-99m by reaction with technetium-99m under reducing conditions.
A complex formed by reacting somatostatin, a derivative of somatostatin, an analog of somatostatin or a peptide that binds to the somatostatin receptor and contains at least 2 cysteine residues that form a disulfide or wherein the disulfide is reduced to the sulfhydryl form, with technetium-99m in the presence of a reducing agent.
A complex formed by ligand exchange of a prereduced technetium-99m complex with somatostatin, a derivative of somatostatin, an analog of somatostatin or a peptide that binds to the somatostatin receptor and contains at least 2 cysteine residues that form a disulfide or wherein the disulfide is reduced to the sulfhydryl form.
A method for imaging a target site within a mammalian body comprising:
- (a) administering an effective diagnostic amount of a peptide that is somatostatin, a derivative of somatostatin, an analog of somatostatin or a peptide that binds to the somatostatin receptor and contains at least 2 cysteine residues that form a disulfide or wherein the disulfide is reduced to the sulfhydryl form which is directly labeled with technetium-99m, wherein the labeled peptide binds to the target site;
- and
- (b) detecting the localized technetium-99m.
Dependencies are inferred from the claim text.